Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University of Illinois, Urbana-Champaign

Division of University of Illinois
otm.illinois.edu

Latest From University of Illinois, Urbana-Champaign

Novartis Swaps Two AveXis Executives For One Following Zolgensma Data Manipulation

The big pharma could not confirm whether AveXis co-founder and CSO Brian Kaspar and his brother, SVP of R&D Allan Kaspar, were fired. Instead, Novartis noted that the withholding of preclinical safety data for Zolgensma was limited to the action of a few employees. NIBR preclinical safety chief takes key role at AveXis

Leadership Gene Therapy

1ST Bio Bets On BBB-Penetrating C-ABL Inhibitor As Potential Disease-Modifying Parkinson's Drug

Emerging Company Profile: 1ST Biotherapeutics CEO highlights its lead candidate program – a novel small molecule c-Abl inhibitor, which touts superior blood-brain penetration and selectivity – for its potential to become a disease-modifying drug for Parkinson's disease.

South Korea StartUps and SMEs

Revolution Medicines Inc.

More than 50% of drugs sold in the US are natural products, or derivatives of them, but drugmakers have long since tired of sifting, sorting, and attempting to synthesize the typically large and complex molecules that nature produces. Revolution Medicines Inc. aims to develop a platform that will break natural products into “building blocks” that medicinal chemists can then assemble and tweak in ways never before possible.

BioPharmaceutical

Start-Up Quarterly Statistics, Q1 2015

In Q1 2015 start-ups raised $2.74 billion, a new record. Biopharma companies penned 37 alliances; 13 start-ups were acquired across all industries.

BioPharmaceutical Medical Device
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register